Peroxisome proliferator-activated receptor γ and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles

Summary

Peroxisome proliferator-activated receptor γ (PPARγ) and its ligands are important regulators of lipid metabolism, inflammation, and diabetes. We previously demonstrated that anucleate human platelets express the transcription factor PPARγ and that PPARγ ligands blunt platelet activation. To further understand the nature of PPARγ in platelets, we determined the platelet PPARγ isoform(s) and investigated the fate of PPARγ following platelet activation. Our studies demonstrated that human platelets contain only the PPARγ1 isoform and after activation with thrombin, TRAP, ADP or collagen PPARγ is released from internal stores. PPARγ release was blocked by a cytoskeleton inhibitor, Latrunculin A. Platelet-released PPARγ was complexed with the retinoid X receptor (RXR) and retained its ability to bind DNA. Interestingly, the released PPARγ and RXR were microparticle associated and the released PPARγ/RXR complex retained DNA-binding ability. Additionally, a monocytic cell line, THP-1, is capable of internalizing PMPs. Further investigation following treatment of these cells with the PPARγ agonist, rosiglitazone and PMPs revealed a possible transcellular mechanism to attenuate THP-1 activation. These new findings are the first to demonstrate transcription factor release from platelets, revealing the complex spectrum of proteins expressed and expelled from platelets, and suggests that platelet PPARγ has an undiscovered role in human biology.

Keywords

Microparticles - peroxisome proliferator-activated receptor γ (PPARγ) - platelets - retinoic X receptor (RXR) - transcription factors

• References

• 1 Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748-759.
• 2 Yanase T, Yashiro T, Takitani K. et al. Differential expression of PPAR γ1 and γ2 isoforms in human adipose tissue. Biochem Biophys Res Commun 1997; 233: 320-324.
• 3 Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol 2002; 103: 22-33.
• 4 Ricote M, Li AC, Willson TM. et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
• 5 Fajas L, Auboeuf D, Raspe E. et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997; 272: 18779-18789.
• 6 Kelly D, Campbell JI, King TP. et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nat Immunol 2004; 5: 104-112.
• 7 Kliewer SA, Umesono K, Noonan DJ. et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-774.
• 8 Lehmann JM, Moore LB, Smith-Oliver TA. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1995; 270: 12953-12956.
• 9 Forman BM, Tontonoz P, Chen J. et al. 15-Deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 1995; 83: 803-812.
• 10 Feldon SE, O’Loughlin C W, Ray DM. et al. Activated Human T Lymphocytes Express Cyclooxygenase- 2 and Produce Proadipogenic Prostaglandins that Drive Human Orbital Fibroblast Differentiation to Adipocytes. Am J Pathol 2006; 169: 1183-1193.
• 11 McIntyre TM, Pontsler AV, Silva AR. et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARg agonist. Proc Natl Acad Sci U S A 2003; 100: 131-136.
• 12 Investigators TDT. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet; prepublished online September 15, 2006, doi:10.1016[S0140-6736(06)69420-8 alpha-granule and dense-granule secretion. Blood 2005; 105: 3879-3887.
• 13 Akbiyik F, Ray DM, Gettings KF. et al. Human bone marrow megakaryocytes and platelets express PPARg, and PPARg agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361-1368.
• 14 Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-2137.
• 15 Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722-729.
• 16 von Hundelshausen P, Petersen F, Brandt E. Platelet- derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704-713.
• 17 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
• 18 Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost 2005; 94: 488-492.
• 19 Blann AD, Tan KT, Tayebjee MH. et al. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93: 578-583.
• 20 Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 2000; 97: 6930-6932.
• 21 Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2003; 2: 775-789.
• 22 Bode AP, Sandberg H, Dombrose FA. et al. Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation. Thromb Res 1985; 39: 49-61.
• 23 Horstman LL, Jy W, Jimenez JJ. et al. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004; 53: 210-230.
• 24 Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897-1905.
• 25 Koppler B, Cohen C, Schlondorff D. et al. Differential mechanisms of microparticle transfer to B cells and monocytes: anti-inflammatory properties of microparticles. Eur J Immunol 2006; 36: 648-660.
• 26 Sims PJ, Wiedmer T, Esmon CT. et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-17057.
• 27 Tans G, Rosing J, Thomassen MC. et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-2648.
• 28 Nomura S, Tandon NN, Nakamura T. et al. Highshear- stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
• 29 Diamant M, Nieuwland R, Pablo RF. et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
• 30 Janowska-Wiexzorek AKJ, Marquez LA, Ratajczak J. et al. Microvesicles derived from activated platelets: an under-appreciated modulator of the metastatic potential of tumor cells. Blood 2003; 102: 57b-3998.
• 31 Ogura M, Morishima Y, Ohno R. et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392.
• 32 Avanzi GC, Brizzi MF, Giannotti J. et al. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3. J Cell Physiol 1990; 145: 458-464.
• 33 Ray DM, Bernstein SH, Phipps RP. Human multiple myeloma cells express peroxisome proliferator- activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands. Clin Immunol 2004; 113: 203-213.
• 34 Kaiser PC, Korner M, Kappeler A. et al. Retinoid receptors in ovarian cancer: expression and prognosis. Ann Oncol 2005; 16: 1477-1487.
• 35 Heijnen HF, Schiel AE, Fijnheer R. et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791-3799.
• 36 Flaumenhaft R, Dilks JR, Rozenvayn N. et al. The actin cytoskeleton differentially regulates platelet.
• 37 Gnatenko DV, Dunn JJ, McCorkle SR. et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-2293.
• 38 Leesnitzer LM, Parks DJ, Bledsoe RK. et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41: 6640-6650.
• 39 von Knethen A, Soller M, Tzieply N. et al. PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J Cell Biol 2007; 176: 681-694.
• 40 Fox JE, Austin CD, Boyles JK. et al. Role of the membrane skeleton in preventing the shedding of procoagulant- rich microvesicles from the platelet plasma membrane. J Cell Biol 1990; 111: 483-493.
• 41 Johnson BA, Wilson EM, Li Y. et al. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 2000; 298: 187-194.
• 42 Pascual G, Fong AL, Ogawa S. et al. A SUMOylation- dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005; 437: 759-763.
• 43 Moraes LA, Swales KE, Wray JA. et al. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 2007; 109: 3741-3744.
• 44 Scholz T, Temmler U, Krause S. et al. Transfer of tissue factor from platelets to monocytes: role of platelet- derived microvesicles and CD62P. Thromb Haemost 2002; 88: 1033-1038.
• 45 Janowska-Wieczorek A, Majka M, Kijowski J. et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001; 98: 3143-3149.
• 46 Singh N, Webb R, Adams R. et al. The PPARgamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium. Biochem Biophys Res Commun 2005; 333: 455-462.
• 47 Sumita C, Maeda M, Fujio Y. et al. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta 2004; 1673: 115-121.